All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA grants orphan drug designation to eprenetapopt for TP53-mutated AML

Apr 13, 2021

Very recently, eprenetapopt (APR-246), a small molecule that reactivates mutant and inactivated p53 protein, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of TP53-mutated acute myeloid leukemia (AML).1

TP53-mutated AML is associated with resistance to treatment and poor prognosis. Eprenetapopt restores wild-type p53 conformation and function, inducing apoptosis in cancer cells. In December 2020, eprenetapopt received FDA fast track designation for AML, as well as FDA breakthrough therapy designation, orphan drug designation, and fast track designation for the treatment of myelodysplastic syndromes (MDS). The agent also holds an orphan drug designation from the European Medicines Agency (EMA) for MDS, AML, and ovarian cancer.

The phase II Groupe Francophone des Myélodysplasies (GFM)-APR trial (NCT03931291) is currently investigating eprenetapopt combined with azacitidine for patients with AML or MDS harboring TP53 mutation. The study results, which can be found here, suggest encouraging safety and efficacy in this patient population.

  1. BioSpace. Aprea Therapeutics receives FDA orphan drug designation for eprenetapopt for the treatment of acute myeloid leukemia (AML). Published Apr 08, 2021. Accessed Apr 12, 2021.